- Home
- NMTC vs NRXP Comparison
NMTC vs NRXP Comparison
Compare NMTC & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMTC
- NRXP
- Stock Information
- Founded
- NMTC 2009
- NRXP 2015
- Country
- NMTC United States
- NRXP United States
- Employees
- NMTC N/A
- NRXP N/A
- Industry
- NMTC Medical/Dental Instruments
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- NMTC Health Care
- NRXP Health Care
- Exchange
- NMTC Nasdaq
- NRXP Nasdaq
- Market Cap
- NMTC 33.8M
- NRXP 58.5M
- IPO Year
- NMTC N/A
- NRXP N/A
- Fundamental
- Price
- NMTC $0.82
- NRXP $2.81
- Analyst Decision
- NMTC Strong Buy
- NRXP Strong Buy
- Analyst Count
- NMTC 1
- NRXP 4
- Target Price
- NMTC $1.45
- NRXP $28.50
- AVG Volume (30 Days)
- NMTC 221.2K
- NRXP 134.9K
- Earning Date
- NMTC 08-13-2025
- NRXP 08-13-2025
- Dividend Yield
- NMTC N/A
- NRXP N/A
- EPS Growth
- NMTC N/A
- NRXP N/A
- EPS
- NMTC N/A
- NRXP N/A
- Revenue
- NMTC $5,758,777.00
- NRXP N/A
- Revenue This Year
- NMTC $157.28
- NRXP N/A
- Revenue Next Year
- NMTC $41.79
- NRXP $230.95
- P/E Ratio
- NMTC N/A
- NRXP N/A
- Revenue Growth
- NMTC 54.53
- NRXP N/A
- 52 Week Low
- NMTC $0.40
- NRXP $1.10
- 52 Week High
- NMTC $1.39
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- NMTC 54.33
- NRXP 35.57
- Support Level
- NMTC $0.81
- NRXP $2.89
- Resistance Level
- NMTC $1.05
- NRXP $3.15
- Average True Range (ATR)
- NMTC 0.08
- NRXP 0.14
- MACD
- NMTC -0.00
- NRXP -0.04
- Stochastic Oscillator
- NMTC 36.67
- NRXP 7.27
About NMTC NeuroOne Medical Technologies Corporation
NeuroOne Medical Technologies Corp operates as a medical technology company. It is focused on the development and commercialization of thin-film electrode technology for continuous electroencephalogram (cEEG) and stereoelectrocencephalography (sEEG) recording, brain stimulation, and ablation solutions for patients suffering from brain-related disorders. The company business is in one operating segment, which is the business of development and commercialization of products related to comprehensive neuromodulation cEEG and sEEG recording, monitoring, ablation, and brain stimulation solutions.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.